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‘‘We still lack the ability to
accurately predict survival
among breast cancer patients
with early-stage disease’’
Advances in hormone therapy and com-
bination chemotherapy have led to signifi-
cant declines in disease recurrence and
mortality due to breast cancer [1,2]. How-
ever, the burden of developing a deadly
disease remains unequal. A disease diagnosis
at age 50 or younger is still more likely to
have a fatal outcome than the same
diagnosis at an older age. Moreover,
African-American women and women di-
agnosed with estrogen, progesterone, and
HER2 receptor–negative disease (termed
triple-negative breast cancer) continue to
experience an excessive mortality and have
not benefited from the advances in breast
cancer therapy as much as other patient
groups [3,4]. Currently,about 10% of breast
cancer patients will succumb to the disease
within the first 5 years following the initial
diagnosis [5], despite many being diagnosed
with an early-stage disease. The relative risk
of dying from breast cancer has a peak
between 2 and 4 years post-diagnosis [2],
and we can only speculate why so many
women die in that period. It remains a great
challenge to prospectively identify those
breast cancer patients who have been
diagnosed with a primary disease but have
a low chance of surviving when treated with
current standard therapy.
A study by Paul Pharoah and colleagues
[6] published in this week’s PLoS Medicine
evaluated immunohistochemistry-based
subtype classification of breast tumors for
prediction of disease outcome. The au-
thors recommend that this method is being
used in clinical practice. Yet, questions
remain of how useful subtype classification
will be in the management of breast
cancer.
Breast Cancer Molecular
Subtypes Are Biologically
Distinct and Have Different
Outcomes
Landmark studies by Perou et al. and by
Sorlie et al. identified five distinct sub-
types, which are different from one
another in their gene expression charac-
teristics [7,8]. They include two estrogen
receptor (ER)-positive subtypes, termed
luminal A and B, and three ER-negative
subtypes, termed basal-like, HER2-posi-
tive, and normal breast-like tumors. Lu-
minal tumors develop more frequently
than the other subtypes and share many
features with luminal epithelial cells lining
the mammary ducts, but tumors in the
luminal B subgroup also aberrantly over-
express the HER2 receptor or prolifera-
tion marker genes that distinguish them
from the HER2-negative luminal A tu-
mors. Basal-like breast cancer has similar-
ities with normal breast basal epithelial
cells and is commonly identified by a lack
of ER and HER2 receptor expression and
by the expression of either cytokeratin 5/6
or epidermal growth factor receptor
(EGFR). This group of tumors is charac-
terized by a high proliferation rate,
pushing border of invasion, and the
frequent expression of cancer stem cell
markers [9]. Basal-like breast tumors share
many features with triple-negative tumors
although the overlap is not complete,
raising the question of whether they
should be treated as two different entities
in clinical practice. A diagnosis of either
the basal-like or triple negative disease
signals a diminished chance of survival
because of high relapse rates within the
first three years after diagnosis, mainly
affecting patients with residual disease
despite the use of adjuvant chemotherapy.
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Linked Research Article
This Perspective discusses the fol-
lowing new study published in PLoS
Medicine:
Blows FM, Driver KE, Schmidt MK,
Broeks A, van Leeuwen FE, et al.
(2010) Subtyping of Breast Cancer
by Immunohistochemistry to Inves-
tigate a Relationship between Sub-
type and Short- and Long-Term
Survival: A Collaborative Analysis
of Data for 10,159 Cases from 12
Studies. PLoS Med 7(5): e1000279.
doi:10.1371/journal.pmed.1000279
Paul Pharoah and colleagues evalu-
ate the prognostic significance of
immunohistochemical subtype clas-
sification in more than 10,000
breast cancer cases with early dis-
ease, and examine the influence of
a patient’s survival time on the
prediction of future survival.
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Numerous studies have shown that
immunohistochemistry for hormone and
EGFR receptors and cytokeratin 5/6
expression is a simple and workable way
to determine the intrinsic subtype of breast
tumors for clinical applications [10,11].
Moreover, immunohistochemical classifi-
cation into either a luminal A, HER2-
expressing, basal-like, or triple-negative
tumors was found to be associated with a
patient’s survival, and tumor subtypes
were shown to respond differently to
adjuvant therapy, with many basal-like
and HER2-positive tumors being particu-
larly sensitive to anthracycline-based com-
bination therapy [12,13]. These findings
suggested that immunohistochemistry-
based classification of breast tumors may
improve prognostication and a patient’s
assignment to therapy beyond current
standards in breast cancer care. However,
several studies challenged this paradigm
and signs emerged that categorization of
breast tumors into good and poor outcome
groups based on their intrinsic subtype
classification may have limitations. Cur-
rently unknown factors seem to further
separate several of the intrinsic subtypes
into two clinically distinct subgroups: one
with patients who succumb to the disease
early and one with patients who continue
to survive the disease [11].
The analysis by Pharoah and colleagues
published in PLoS Medicine evaluated the
prognostic significance of immunohisto-
chemical subtype classification in over
10,000 cases with early disease, examining
the influence of a patient’s survival time on
the prediction of future survival [6]. The
authors subtyped breast tumors into HER2-
negative and HER2-positive luminal tu-
mors, HER2-positive ER-negative tumors,
tumors with the core basal phenotype
(‘‘basal-like’’) and tumors that lacked expres-
sion of the estrogen, progesterone, and
HER2 receptors and also cytokeratin 5/6
and EGFR (‘‘triple-negative tumors that are
not basal-like’’). Consistent with existing
literature, short- and long-term survival of
breast cancer patients was found to differ by
subtype, arguing that subtype classification is
clinically useful and will help determine
appropriate therapies. The authors also
provided more evidence that basal-like
tumors are clinically distinct from triple-
negative tumors.
However, in contrast to many previous
reports, a simple categorization of basal-like,
triple-negative, or HER2-positive tumors as
poor-outcome subtypes is not supported by
this new study. Instead, initial differences in
survival between subtypes were found to
change with increasing survival time, and all
previously described poor-outcome sub-
types, when compared to ER-positive,
HER2-negative tumors, became in fact
good outcome subtypes if patients survived
longer than five years.The observed survival
patterns were independent of any systemic
adjuvant therapy, suggesting that tumor
biology and molecular heterogeneity within
breast cancer subtypes, rather than the
choice of therapy, determined the survival
trends.
How robust are the findings from this
new study? The strength of the study is
clearly its size and the careful analysis of
differences in patient survival by tumor
subtype including the calculation of peri-
od-specific hazard ratios. However, some
limitations may arise from the use of
pooled data from 12 independent studies,
possibly introducing heterogeneity and
misclassification errors, the predominance
of ER-positive, HER2-negative tumors in
the study population, and the limited
racial/ethnic diversity of the patients.
Nevertheless, these limitations should not
challenge the validity and broad implica-
tion of the findings.
Is There a Limitation to Subtype
Classification for
Prognostication and Targeted
Therapy?
Pharoah and colleagues describe a pat-
tern for short- and long-term breast cancer
survival that reflects a constant mortality
rate for ER-positive, HER2-negative tumors
and a bimodal mortality rate pattern for all
other breast cancer subtypes, with an
initiallyhighmortality rate that progressively
declines. Changes in mortality rates and
disease prognosis with increasing survival
time will complicate decision making in
clinical practice. What causes mortality rates
to change when patients survived the first
years after diagnosis? It is partly explained
by the excess risk of early relapse, leading to
excessmortalitywithinthefirstfiveyears,for
patients that have residual disease and have
been diagnosed with a basal-like, triple-
negative, or HER2-positive tumor. It ap-
p e a r st h a tt h e s er e l a p s i n gp a t i e n t sc a n n o tb e
saved by current standard therapy. It is a
limitation of the immunohistochemistry
approach applied by Pharoah and col-
leagues, and of the intrinsic breast cancer
subtype model in general, that it cannot
differentiate within a subtype between those
patients who will succumb to the disease
within a few years and those who will
continue to survive the disease. It is unlikely
that other prediction models will do much
better. Several gene expression signatures
developed for prognostication showed high
rates of concordance with the intrinsic
subtype model in their outcome prediction,
and assigned similar recurrence scores to
individual tumors [14].
Clinical Implications
Two key areas of uncertainty exist in the
management of breast cancer. The first
deals with the problem of identifying
patients who are the most appropriate
candidates for receiving adjuvant therapy.
Adjuvant systemic therapy significantly
improves survival of breast cancer pa-
tients. However, many patients with early-
stage disease may not need adjuvant
systemic therapy. Gene signature–derived
tumor markers can assist in selecting those
patients who will benefit most from
adjuvant therapy [15]. Thus, immunohis-
tochemistry-based subtype classification
holds the promise that it can be used
clinically in directing patients to the most
appropriate therapy choice. The other key
area is to identify those patients who are at
a high risk of disease recurrence and
mortality, and who will not respond to
current standard therapy. Subtype classi-
fication may not be very useful in
identifying those patients. Currently, we
do not know whether increased metastatic
potential, intrinsic drug resistance, or a
combination of both is the culprit that
makes a subset of primary tumors so
deadly. Basal-like tumors tend to develop
visceral metastases more commonly than
other tumor subtypes, and it has been
hypothesized that these tumors have a
distinct molecular mechanism of metastat-
ic spread that may evade detection [16].
Moreover, these tumors and triple-nega-
tive tumors may share molecular defects in
their DNA repair capacity, which makes
them sensitive to certain classes of DNA-
damaging therapeutics. This hypothesis
should be explored. Lastly, we need
additional research to develop markers
that can differentiate between those pa-
tients who will relapse early and those who
will survive. Some studies have begun to
characterize tumors from relapsing pa-
tients [12]. If successful, a molecular
profile should emerge that will aid in the
development of more targeted therapies
that can eradicate these tumors.
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